Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. 09 Apr 2024  |  North America

    US and European Home Care Digitalization Growth Opportunities Forecast to 2028

    Technology will Support Consumer Preferences for Receiving Care in the Comfort of Home

    Home has become an attractive care delivery site because of the convenience, affordability, and patient-centric care environment it offers. The home care digitalization industry represents technologies that home care agencies use to improve/enhance services for the end user (B2B2C). The industry picked up pace during the COVID-19 pandemic and has s...

    $4,950.00
  2. 31 Jan 2024  |  North America

    Digital Health Regulations in North America and Europe: Growth Opportunities 2023

    Innovative Business Models and Technologies are Leading to the Introduction of Disruptive Regulations

    This report examines the regulations surrounding digital health in North America and Europe. It provides a general analysis of key national and regional regulatory updates that will impact digital health players and influence market dynamics. The regulatory documents considered are those governing the healthcare sector and applicable to digital hea...

    $2,450.00
  3. 18 Jan 2024  |  Global

    Top 5 Growth Opportunities in Digital Health, 2024

    How Disruptive Technologies are Changing Business Models

    The healthcare landscape is experiencing a profound shift as it shifts away from traditional fee-for-service models toward value-based care. This transition emphasizes collaboration among healthcare stakeholders, fostering a patient-centric approach. The focus is not merely on the quantity of services delivered but also on the quality of care, enco...

    $2,450.00
  4. 30 Mar 2023  |  North America

    Global Laboratory Product Purchasing Trends, 2022–2023

    End–user Perspectives on Laboratory Spending Reveals Modest 2023 Budget Increases Following robust 2022 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey from October to November 2022 examining their laboratories’ product purchasing process in 2022 and expectations for 2023. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. The study presents year-o...

    $4,950.00
  5. 26 Mar 2021  |  North America

    Global Laboratory Product Purchasing Trends, 2020–2021

    An End-user Perspective on Laboratory Spending Reveals Modest 2021 Budget Increases Following Healthier 2020 Spending

    Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents yea...

    $4,950.00
  6. 27 Aug 2020  |  Global

    Smart Labs as Key Drivers for the Digital Transformation of Diagnostic Laboratories, 2020

    Robotic Automation, Internet of Things (IoT), and Artificial Intelligence (AI) Offering Growth Opportunities for Academic and Commercial Diagnostics Labs

    Diagnostic academic and commercial research labs suffer from cost pressures, given the ongoing Protecting Access to Medicare Act (PAMA) regulations and reproducibility issues, and are under productivity strain. The recent COVID-19 pandemic leading to increasing test volumes and renewed focus on research and development (R&D) to drive innovation wil...

    $3,000.00
  7. 31 Jan 2020  |  North America

    Predictions for the Global Life Sciences Industry, 2020

    COVID-19 Pandemic will Drive New Digital-tech Adoption in Drug Discovery and Testing Services, and Federal Funding will Encourage Stronger Product Pipelines

    The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

    $1,500.00
  8. 27 Jan 2020  |  Global

    Growth Opportunities—Contract Manufacturing and Outsourcing Opportunities in the In-vitro Diagnostics (IVD) Industry, 2019 to 2022

    Consolidation and Innovative Business Models Will Accelerate IVD Outsourcing Growth

    The increasing pressure for cost-driven development and regulatory and regional trends are inducing industry participants to adopt innovative integrated business models so as to align themselves as one-stop-shop solution providers as opposed to the traditional functional service providers, thereby, creating a mutually beneficial symbiotic relations...

    $4,950.00
  9. 10 Jan 2020  |  Asia Pacific

    Growth Insights on China’s Pharmaceutical Industry, Forecast to 2025

    Expedited Regulatory Reviews, Accompanied by Surging Novel Drug Pipelines and a Realigned Distribution System will Propel the Chinese Pharma Industry

    With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

    $10,000.00
  10. 02 Dec 2019  |  North America

    Growth Opportunities in the Global Pharmaceutical Contract Manufacturing Organization Market (CMO), Forecast to 2024

    Advancements in Continuous Manufacturing Technology, Necessary to Meet New Demand in the Orphan Drugs Segment and Personalized Medicine, Will Give a New Growth Vector to CMOs

    Traditionally, CMOs have thrived by aggregating demand and delivering benefits of economies of scale. However, with the fading era of blockbuster drugs dispensed to large patient pools and shift to precision medicine, focus on niche indications, and increased R&D in biologics, pharma sponsors are increasingly turning to CMOs as strategic partners i...

    $4,950.00